XML 19 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
Total
Convertible senior notes
August 2019 Bonds
Preferred stock
Common stock
Common stock
Convertible senior notes
Common stock
August 2019 Bonds
Additional paid-in capital
Additional paid-in capital
Convertible senior notes
Additional paid-in capital
August 2019 Bonds
Accumulated deficit
Accumulated other comprehensive income (loss)
Non- controlling interest
Beginning balance (in shares) at Dec. 31, 2019       23 101,361,034                
Beginning balance at Dec. 31, 2019 $ 5,404,858     $ 0 $ 101,361     $ 742,646,785     $ (739,785,655) $ 472,608 $ 1,969,759
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Issuance of common stock for cash, net of financing costs (in shares)         43,148,952                
Issuance of common stock for cash, net of financing costs 208,241,933       $ 43,149     208,198,784          
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)         1,405,114                
Exercise of stock options for cash and vesting of RSUs, net of tax payments 3,100,703       $ 1,405     3,099,298          
Stock-based compensation 4,001,553             4,017,761         (16,208)
Acquisition of non-controlling interest in Geneos 2,169,998                       2,169,998
Net loss attributable to common stockholders (33,135,404)                   (32,541,054)   (594,350)
Unrealized gain (loss) on short-term investments, net of tax (1,929,538)                     (1,929,538)  
Ending balance (in shares) at Mar. 31, 2020       23 145,915,100                
Ending balance at Mar. 31, 2020 187,854,103     $ 0 $ 145,915     957,962,628     (772,326,709) (1,456,930) 3,529,199
Beginning balance (in shares) at Dec. 31, 2019       23 101,361,034                
Beginning balance at Dec. 31, 2019 5,404,858     $ 0 $ 101,361     742,646,785     (739,785,655) 472,608 1,969,759
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss attributable to common stockholders (143,136,534)                        
Unrealized gain (loss) on short-term investments, net of tax (726,626)                        
Foreign currency translation 6,184                        
Ending balance (in shares) at Sep. 30, 2020       9 167,528,435                
Ending balance at Sep. 30, 2020 324,000,115     $ 0 $ 167,527     1,205,842,585     (881,858,432) (247,834) 96,269
Beginning balance (in shares) at Mar. 31, 2020       23 145,915,100                
Beginning balance at Mar. 31, 2020 187,854,103     $ 0 $ 145,915     957,962,628     (772,326,709) (1,456,930) 3,529,199
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Issuance of common stock for cash, net of financing costs (in shares)         12,041,178                
Issuance of common stock for cash, net of financing costs 121,718,922       $ 12,041     121,706,881          
Conversion of preferred stock to common stock (in shares)       14 5,147                
Conversion of preferred stock to common stock 0       $ 5     (5)          
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)         794,986                
Exercise of stock options for cash and vesting of RSUs, net of tax payments 4,422,244       $ 795     4,421,449          
Stock-based compensation 3,662,435             3,654,289         8,146
Acquisition of non-controlling interest in Geneos 209,971                       209,971
Deconsolidation of Geneos (3,181,640)                       (3,181,640)
Net loss attributable to common stockholders (129,172,466)                   (128,703,059)   (469,407)
Unrealized gain (loss) on short-term investments, net of tax 846,900                     846,900  
Ending balance (in shares) at Jun. 30, 2020       9 158,756,411                
Ending balance at Jun. 30, 2020 186,360,469     $ 0 $ 158,756     1,087,745,242     (901,029,768) (610,030) 96,269
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Conversion of preferred stock to common stock (in shares)           3,546,074 4,962,364            
Conversion of preferred stock to common stock   $ 12,971,360 $ 102,671,310     $ 3,546 $ 4,961   $ 12,967,814 $ 102,666,349      
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)         263,586                
Exercise of stock options for cash and vesting of RSUs, net of tax payments (1,695,051)       $ 264     (1,695,315)          
Stock-based compensation 4,158,495             4,158,495          
Acquisition of non-controlling interest in Geneos 0                        
Net loss attributable to common stockholders 19,171,336                   19,171,336    
Unrealized gain (loss) on short-term investments, net of tax 356,012                     356,012  
Foreign currency translation 6,184                     6,184  
Ending balance (in shares) at Sep. 30, 2020       9 167,528,435                
Ending balance at Sep. 30, 2020 324,000,115     $ 0 $ 167,527     1,205,842,585     (881,858,432) (247,834) $ 96,269
Beginning balance (in shares) at Dec. 31, 2020       9 186,851,493                
Beginning balance at Dec. 31, 2020 461,140,758     $ 0 $ 186,851     1,367,406,869     (906,196,812) (256,150)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Issuance of common stock for cash, net of financing costs (in shares)         20,355,000                
Issuance of common stock for cash, net of financing costs 162,105,030       $ 20,355     162,084,675          
Conversion of preferred stock to common stock (in shares)         1,009,450                
Conversion of preferred stock to common stock 4,377,892       $ 1,009     4,376,883          
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)         1,118,093                
Exercise of stock options for cash and vesting of RSUs, net of tax payments (1,201,789)       $ 1,118     (1,202,907)          
Stock-based compensation 9,595,947             9,595,947          
Net loss attributable to common stockholders (54,402,131)                   (54,402,131)    
Unrealized gain (loss) on short-term investments, net of tax 4,861                     4,861  
Foreign currency translation (14,419)                     (14,419)  
Ending balance (in shares) at Mar. 31, 2021       9 209,334,036                
Ending balance at Mar. 31, 2021 581,606,149     $ 0 $ 209,333     1,542,261,467     (960,598,943) (265,708)  
Beginning balance (in shares) at Dec. 31, 2020       9 186,851,493                
Beginning balance at Dec. 31, 2020 461,140,758     $ 0 $ 186,851     1,367,406,869     (906,196,812) (256,150)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss attributable to common stockholders (196,711,130)                        
Unrealized gain (loss) on short-term investments, net of tax 21,031                        
Foreign currency translation (22,813)                        
Ending balance (in shares) at Sep. 30, 2021       9 210,362,834                
Ending balance at Sep. 30, 2021 453,572,379     $ 0 $ 210,362     1,556,527,891     (1,102,907,942) (257,932)  
Beginning balance (in shares) at Mar. 31, 2021       9 209,334,036                
Beginning balance at Mar. 31, 2021 581,606,149     $ 0 $ 209,333     1,542,261,467     (960,598,943) (265,708)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)         812,844                
Exercise of stock options for cash and vesting of RSUs, net of tax payments 3,441,423       $ 813     3,440,610          
Stock-based compensation 5,646,358             5,646,358          
Net loss attributable to common stockholders (82,139,958)                   (82,139,958)    
Unrealized gain (loss) on short-term investments, net of tax (2,679)                     (2,679)  
Foreign currency translation 2,478                     2,478  
Ending balance (in shares) at Jun. 30, 2021       9 210,146,880                
Ending balance at Jun. 30, 2021 508,553,771     $ 0 $ 210,146     1,551,348,435     (1,042,738,901) (265,909)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)         215,954                
Exercise of stock options for cash and vesting of RSUs, net of tax payments (440,780)       $ 216     (440,996)          
Stock-based compensation 5,620,452             5,620,452          
Net loss attributable to common stockholders (60,169,041)                   (60,169,041)    
Unrealized gain (loss) on short-term investments, net of tax 18,849                     18,849  
Foreign currency translation (10,872)                     (10,872)  
Ending balance (in shares) at Sep. 30, 2021       9 210,362,834                
Ending balance at Sep. 30, 2021 $ 453,572,379     $ 0 $ 210,362     $ 1,556,527,891     $ (1,102,907,942) $ (257,932)